Hadim AKOĞLU, Başol CANBAKAN, Ebru GÖK OĞUZ, Mehmet Deniz AYLI, Zafer ERCAN, Özgür MERHAMETSİZ, Gülay ULUSAL OKYAY, Güner KARAVELİ GÜRSOY

The impact of calcineurin inhibitors and mammalian target of rapamycininhibitors on anxiety and depression scores in kidney transplant patients

Background/aim: Depression and anxiety are prevalent symptoms in kidney transplant patients. We aimed to evaluate the frequency and the severity of depression and anxiety symptoms in kidney transplant recipients using the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). The data were compared between the patients on CNI-based and mTORi-based maintenance immunosuppressive regimens. Materials and methods: A total of 94 kidney transplant patients were enrolled in the study after exclusion of the patients already taking neuropsychiatric medications or unwilling to participate in the study. Participants were asked to self-report the inventories. Results: Analysis of data showed that 62 (66%) recipients had BDI scores that indicated depression. The patients on CNI-based regimens (n = 74) had increased total BDI scores compared those on mTORi-based regimens [18 (8.75 28) vs. 6 (5.25 14.25), respectively, P < 0.001]. Regarding BAI scores, 79 patients (84%) had prominent anxiety symptoms. The patients on CNI-based regimens had significantly increased total BAI scores compared to those on mTORi-based regimens [21 (13 30.50) vs. 10.50 (8.25 14.75), respectively, P < 0.001]. Conclusion: Our results identified fewer side effects of mTORi-based maintenance immunosuppressive regimens regarding depression and anxiety symptoms compared to CNI-based regimens in kidney transplant patients.

PDF

___

1. Hunsicker LG. A survival advantage for renal transplantation. N Engl J Med. 1999; 341: 1762-1763.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
3. Nankivell B, Borrow R, Fung Cl, OConnell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565.
4. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant Int 2000; 13: 313-326.
5. Cardinal H, Froidure A, Dandavino R, Daloze P, Hébert MJ, Colette S, Boucher A. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study. Transplant Proc 2009; 41: 3308-3310.
6. Martínez-Sanchis S, Bernal MC, Montagud JV, Candela G, Crespo J, Sancho A, Pallardó LM. Effects of immunosuppressive drugs on the cognitive functioning of renal transplant recipients: a pilot study. J Clin Exp Neuropsychol 2011; 33: 1016-1024.
7. Abbott KC, Agodoa LY, OMalley PG. Hospitalised psychoses after renal transplantation in the United States: incidence, risk factors, and prognosis. J Am Soc Nephrol 2003; 14: 1628-1635.
8. Wada K, Yamada N, Sato T, Suzuki H, Miki M, Lee Y, Akiyama K, Kuroda S. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics 2001; 42: 461-466.
9. Griva K, Hansraj S, Thompson D, Jayasena D, Davenport A, Harrison M, Newman SP. Neuropsychological performance after kidney transplantation: a comparison between transplant types and in relation to dialysis and normative data. Nephrol Dial Transplant 2004; 19: 1866-1874.
10. Lang UE, Heger J, Willbring M, Domula M, Matschke K, Tugtekin SM. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement. Transplant Proc 2009; 41: 4285-4288.
11. Beck AT, Waed CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
12. Hisli N. Beck depression inventory of university students on the validity and reliability. J Psychol 1989; 7: 3-13.
13. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56: 893-897.
14. Eren I, Sahin M, Tunc SE, Cure E, Civi II. Psychiatric symptoms and quality of life in patients with Behçets disease. Neurol Psychiatr Brain Res 2006; 13: 169-174.
15. Novac M, Molnar MZ, Szeifert L, Kovacs AZ, Vamos EP, Zoller R, Keszei A, Mucsi I. Depressive symptoms and mortality in patients after kidney transplantation: a prospective prevalent cohort study. Psychosom Med 2010; 72: 527-534.
16. Arapaslan B, Soykan A, Soykan C, Kumbasar H. Cross-sectional assessment of psychiatric disorders in renal transplantation patients in Turkey: a preliminary study. Transplant Proc 2004; 36: 1419-1421.
17. Noohi S, Khaghani-Zadeh M, Javadipour M, Assari S, Najafi M, Ebrahiminia M, Pourfarziani V. Anxiety and depression are correlated with higher morbidity after kidney transplantation. Transplant Proc 2007; 39: 1074-1078.
18. Anvar-Abnavi M, Bazargani Z. Prevalence of anxiety and depression in Iranian kidney transplant recipients. Neurosciences (Riyadh) 2010; 15: 254-257.
19. Zhu WL, Shi HS, Wang SJ, Wu P, Ding ZB, Lu L. Hippocampal CA3 calcineurin activity participates in depressive-like behavior in rats. J Neurochem 2011; 117: 1075-1086.
20. Crozatier C, Farley S, Mansuy IM, Dumas S, Giros B, Tzavara ET. Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants. Neuroscience 2007; 144: 1470-1476.
21. Bahi A, Mineur YS, Picciotto MR. Blockade of protein phosphatase 2B activity in the amygdala increases anxiety and depression-like behaviors in mice. Biol Psychiatry 2009; 66: 1139-1146.
22. Mineur YS, Taylor SR, Picciotto MR. Calcineurin downregulation in the amygdala is is sufficient to induce anxiety-like and depression-like behaviors in C57BL/6 male mice. Biol Psychiatry 2014; 75: 991-998.
23. Bekinschtein P, Katche C, Slipczuk LN, Igaz LM, Cammarota M, Izquierdo I, Medina JH. mTOR signaling in the hippocampus is necessary for memory formation. Neurobiol Learn Mem 2007; 87: 303-307.
24. Botterill JJ, Brymer KJ, Caruncho HJ, Kalynchuk LE. Aberrant hippocampal neurogenesis after limbic kindling: relationship to BDNF and hippocampal-dependent memory. Epilepsy Behav 2015; 47: 83-92.
25. Grados M, Sung HM, Kim S, Srivastava S. Genetic findings in obsessive-compulsive disorder connect to brain-derived neutrophic factor and mammalian target of rapamycin pathways: implications for drug development. Drug Dev Res 2014; 75: 372-383.
26. Lang UE, Hellweg R, Gallinat J. BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004; 29: 795- 798.
27. Lang UE, Hellweg R, Kalus P, Bajbouj M, Lenzen KP, Sander T, Kunz D, Gallinat J. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 2005; 180: 95-99.
28. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-2347.
29. Eidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M, Jain A, Takaya S, Todo SN, Tzakis A, Van Thiel D. Neurologic complications of FK-506. Transplant Proc 1991; 23: 3175-3178.
30. Sayin A, Mutluay R, Sindel S. Quality of life in hemodialysis, peritoneal dialysis, and transplantation patients. Transplant Proc 2007; 39: 3047-3053.
31. Akman B, Ozdemir FN, Sezer S, Miçozkadioglu H, Haberal M. Depression levels before and after renal transplantation. Transplant Proc 2004; 36: 111-113.
32. Lorant V, Deliège D, Eaton W, Robert A, Philippot P, Ansseau M. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol 2003; 157: 98-112.
33. Feroze U, Martin D, Reina-Patton A, Kalantar-Zadeh K, Kopple JD. Mental health, depression, and anxiety in patients on maintenance dialysis. Iran J Kidney Dis 2010; 4: 173-180.
34. Stasiak CE, Bazan KS, Kuss RS, Schuinski AF, Baroni G. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol 2014; 36: 325-331.
35. Parsaei Mehr Z, Hami M, Moshtagh Eshgh Z. Anxiety and depression: a comparison between living and cadaveric renal transplant recipients. Int J Organ Transplant Med 2011; 2: 178- 183.
36. Nickel R, Wunsch A, Egle UT, Lohse AW, Otto G. The relevance of anxiety, depression, and coping in patients after liver transplantation. Liver Transplant 2002; 8: 63-71.
37. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: metaanalysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101-2107.
38. Penkower L, Dew MA, Ellis D, Sereika SM, Kitutu JM, Shapiro R. Psychological distress and adherence to the medical regimen among adolescent renal transplant recipients. Am J Transplant 2003; 3: 1418-1425.